We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Exiqon's miRCURY LNA™ microRNA Array Product Line Selected as Preferred Platform by Multinational Company

Read time: Less than a minute
Exiqon A/S has announced that Dr. Alain Sewer, Phillip Morris International, R&D, Neuchatel, Switzerland, has presented data from a comprehensive validation study of the miRCURY LNA™ microRNA Array product line.

Dr. Sewer's data demonstrate that the LNA™-enhanced capture probes secure specific detection of microRNAs in complex samples. The study concludes that Exiqon's miRCURY LNA™ microRNA Array platform outperforms similar products provided by a main competitor.

Exiqon's microRNA arrays feature Tm-normalized, LNA™-enhanced capture probes, designed by advanced bioinformatics algorithms for specificity and sensitivity for all microRNAs in more than 100 different species.

The miRCURY LNA™ microRNA Array product line includes the miRCURY LNA™ microRNA Arrays, miRCURY LNA™ microRNA Power Labeling Kits and the miRCURY LNA™ microRNA Array Analysis Software. The products are provided with protocols for a number of different instrument platforms.

”We are always pleased when a major international customer publishes the conclusions from their internal validation studies. In this publication, it is demonstrated that Exiqon's products are superior in terms of sensitivity and specificity which represent the most important values for our customers”, said Henrik M. Pfundheller, VP Sales & Marketing at Exiqon.
Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.